Program
pelacarsen
Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.
Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.
Drug pagePelacarsen: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 104 open or running | phase 3since Jul 16, 2019 | Jul 16, 2019 | Feb 3, 2028phase 3 · NCT06813911 |
| Ionis Pharmaceuticals | 60 open or running | phase 2since Jan 31, 2017 | Apr 1, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ionis Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 1, 2015First study: phase 1 study in Elevated Lipoprotein(a)First studyNCT02414594 · 60 enrolled · Canada
- Jan 31, 2017Phase 2 study in Cardiovascular DiseasesNCT03070782 · 286 enrolled · United States, Canada, Denmark and more
- Jan 2, 20182 phase 1 studies in Cardiovascular DiseasesNCT03392051, NCT03426033
- Apr 3, 2018Phase 1 study in Renal InsufficiencyNCT03506854 · 16 enrolled · United States, Canada
- Dec 9, 2019Named pelacarsenINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ISIS 681257, TQJ230
- Apr 13, 2022Phase 1 study in Healthy ParticipantsNCT05337878 · 29 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 Ionis Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05337878Healthy Participants · United States | 1 | Completed | Dec 18, 2019 | 29 |
| NCT03506854Renal Insufficiency · United States, Canada | 1 | Completed | Oct 11, 2018 | 16 |
| NCT03426033Cardiovascular Diseases · Canada | 1 | Completed | Feb 25, 2018 | 18 |
| NCT03392051Cardiovascular Diseases · Canada | 1 | Completed | Mar 18, 2018 | 18 |
| NCT03070782Cardiovascular Diseases · United States, Canada, Denmark and more | 2 | Completed | Jul 26, 2018 | 286 |
| NCT02414594Elevated Lipoprotein(a) · Canada | 1 | Completed | Feb 2016 | 60 |
How it is read
Names in the registry
- “Pelacarsen”, 5 entries
- “ISIS 681257”, 4 entries
- “Pelacarsen (TQJ230)”, 2 entries
- “TQJ230”, 2 entries
- “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 7 studies
- Atherosclerosis, 2 studies
- Hyperlipoproteinemias, 1 study
- Acute Coronary Syndrome, 1 study
- Aortic Valve Stenosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.